- Trials with a EudraCT protocol (26)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
26 result(s) found for: Biomarkers of aging.
Displaying page 1 of 2.
EudraCT Number: 2021-003299-15 | Sponsor Protocol Number: METFORAGING | Start Date*: 2021-10-19 |
Sponsor Name:Fundación para la Investigación Biomédica del Hospital La Paz | ||
Full Title: A double blinded, phase II, placebo controlled, single center randomized clinical trial to evaluate metformin compared with placebo for reversal of accelerated biological aging in persons living wi... | ||
Medical condition: Patients with HIV and accelerated biological aging | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-000650-21 | Sponsor Protocol Number: PHARMADIPOAGE | Start Date*: 2018-10-31 | |||||||||||
Sponsor Name:Universidad Autónoma de Madrid | |||||||||||||
Full Title: CLINICAL TRIAL FOR EVALUATION OF THE ADIPOQUINAS: NEW PHARMACOLOGICAL TARGETS TO PREVENT VASCULAR AGING | |||||||||||||
Medical condition: PREDIABETES | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-002147-10 | Sponsor Protocol Number: FLU-MARK | Start Date*: 2011-09-21 | ||||||||||||||||
Sponsor Name:Institute for Biomedical Aging Research | ||||||||||||||||||
Full Title: Influenza vaccination in old age: Immunological and biogerontological characterization of responders and non-responders | ||||||||||||||||||
Medical condition: This study will analyze cellular and humoral immune responses after seasonal vaccination against influenza. Healthy adults are vaccinated with a licensed trivalent inactivated vaccine without adjuv... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: AT (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002060-17 | Sponsor Protocol Number: 2015/077/HP | Start Date*: 2015-08-21 | |||||||||||||||||||||
Sponsor Name:CHU - Hôpitaux de Rouen | |||||||||||||||||||||||
Full Title: Effect of pharmacological heart rate reduction on visco-elastic properties of the arterial wall - Impact of aging | |||||||||||||||||||||||
Medical condition: Healthy subjects between 25 and 65 years old | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: FR (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-000266-11 | Sponsor Protocol Number: 2012-772 | Start Date*: 2014-05-27 |
Sponsor Name:HOSPICES CIVILS DE LYON | ||
Full Title: Multicenter, randomized trial of carboplatin +/- paclitaxel in vulnerable elderly patients with stage III-IV advanced ovarian cancer. | ||
Medical condition: Vulnerable elderly women with newly diagnosed stage III-IV ovarian cancer after an initial debulking surgery or with a planned interval debulking surgery. | ||
Disease: | ||
Population Age: Elderly | Gender: Female | |
Trial protocol: IT (Completed) IE (Completed) DK (Prematurely Ended) FI (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-003473-94 | Sponsor Protocol Number: UCL-2016-121 | Start Date*: 2019-05-20 |
Sponsor Name:Cliniques Universitaires Saint-Luc | ||
Full Title: Tau and Amyloid PET imaging in normal aging, early Alzheimer's disease and related syndroms. | ||
Medical condition: Alzheimer’s disease (AD) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2020-004848-29 | Sponsor Protocol Number: NN6535-4730 | Start Date*: 2021-04-29 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer´s disease (EVOKE) | |||||||||||||
Medical condition: Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) CZ (Trial now transitioned) DE (Trial now transitioned) FI (Trial now transitioned) IE (Trial now transitioned) SK (Trial now transitioned) NL (Trial now transitioned) AT (Trial now transitioned) BE (Trial now transitioned) SI (Trial now transitioned) DK (Trial now transitioned) GR (Trial now transitioned) PL (Trial now transitioned) NO (Trial now transitioned) PT (Trial now transitioned) BG (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003288-20 | Sponsor Protocol Number: BN29553 | Start Date*: 2017-05-07 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd. | |||||||||||||
Full Title: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, EFFICACY AND SAFETY STUDY OF CRENEZUMAB IN PATIENTS WITH PRODROMAL TO MILD ALZHEIMER’S DISEASE | |||||||||||||
Medical condition: Alzheimer’s Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) ES (Prematurely Ended) EE (Prematurely Ended) PT (Prematurely Ended) BE (Completed) DE (Prematurely Ended) GR (Prematurely Ended) FR (Completed) SE (Prematurely Ended) DK (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004400-19 | Sponsor Protocol Number: 1707-FIVI-084-MV | Start Date*: 2019-05-30 | |||||||||||
Sponsor Name:IVIRMA MADRID | |||||||||||||
Full Title: Study of the effects of telomerase reactivation with Danazol on ovarian function. A Pilot Study. | |||||||||||||
Medical condition: low ovarian reserve | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003620-16 | Sponsor Protocol Number: IIV-465 | Start Date*: 2021-05-27 |
Sponsor Name:National Institute of Health and the Environment | ||
Full Title: Vaccine immunogenicity in Dutch frail versus non-frail older individuals (participating in the Doetinchem Cohort study) | ||
Medical condition: Older adults 73-79 years of age, birth cohorts year 1941-1947, still participating in round 6 of the Doetinchem Cohort Study. | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-004864-25 | Sponsor Protocol Number: NN6535-4725 | Start Date*: 2021-04-29 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer´s disease (EVOKE plus) | |||||||||||||
Medical condition: Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) CZ (Trial now transitioned) DE (Trial now transitioned) FI (Trial now transitioned) IE (Trial now transitioned) SK (Trial now transitioned) NL (Trial now transitioned) AT (Trial now transitioned) BE (Trial now transitioned) SI (Trial now transitioned) DK (Trial now transitioned) GR (Trial now transitioned) PL (Trial now transitioned) PT (Trial now transitioned) BG (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) HR (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000413-48 | Sponsor Protocol Number: 8.1(IRE),2017.03.24 | Start Date*: 2015-07-01 |
Sponsor Name:ACS Biomarker | ||
Full Title: Bioprofiling response to mineralocorticoid receptor antagonists for the prevention of heart failure. A proof of concept clinical trial within the EU FP 7 “HOMAGE” programme « Heart OMics in AGing | ||
Medical condition: Elderly patients with Clinical and Biological risk factors for developing heart failure | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IE (Prematurely Ended) NL (Prematurely Ended) GB (Prematurely Ended) DE (Completed) IT (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2020-005755-20 | Sponsor Protocol Number: ALZ-801-AD301 | Start Date*: 2021-06-21 | |||||||||||
Sponsor Name:Alzheon, Inc. | |||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects with Early Alzheimer's Disease and APOE4/4 Genotype | |||||||||||||
Medical condition: Early Alzheimer’s Disease (AD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) DE (Completed) NL (Completed) ES (Completed) CZ (Completed) IS (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004128-42 | Sponsor Protocol Number: E2609-G000-302 | Start Date*: 2017-07-25 | |||||||||||||||||||||
Sponsor Name:Eisai Ltd. | |||||||||||||||||||||||
Full Title: A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimer’s Disease | |||||||||||||||||||||||
Medical condition: Early Alzheimer Disease including mild cognitive impairment (MCI) due to AD/Prodromal AD and the early stages of mild AD | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) ES (Prematurely Ended) PL (Prematurely Ended) CZ (Completed) PT (Prematurely Ended) FI (Prematurely Ended) HU (Completed) FR (Completed) DK (Prematurely Ended) IT (Prematurely Ended) HR (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-003154-40 | Sponsor Protocol Number: MK-4305-061 | Start Date*: 2017-01-11 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of Suvorexant (MK-4305) for the Treatment of Insomnia in Subjects with Alzheimer’s Disease | |||||||||||||
Medical condition: Insomnia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003567-66 | Sponsor Protocol Number: T817MAEU201 | Start Date*: 2019-06-11 | ||||||||||||||||
Sponsor Name:FUJIFILM Toyama Chemical Co., Ltd. | ||||||||||||||||||
Full Title: A Phase 2 multi-center, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of T 817MA in patients with mild cognitive impairment due to Alzheimer... | ||||||||||||||||||
Medical condition: Mild cognitive impairment due to Alzheimer's Disease or mild Alzheimer's Disease. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) NL (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) ES (Ongoing) HU (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000948-42 | Sponsor Protocol Number: 54861911ALZ2003 | Start Date*: 2015-12-14 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Study Investigating the Efficacy and Safety of JNJ-54861911 in Subjects who are Asymptomatic At Risk for Devel... | |||||||||||||
Medical condition: Alzheimer's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) DE (Prematurely Ended) DK (Prematurely Ended) BE (Completed) ES (Completed) FI (Prematurely Ended) NL (Temporarily Halted) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003928-23 | Sponsor Protocol Number: E2609-G000-301 | Start Date*: 2017-08-11 | |||||||||||||||||||||
Sponsor Name:Eisai Ltd. | |||||||||||||||||||||||
Full Title: A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study with an Open-Label Extension Phase to Evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimer’s Disease | |||||||||||||||||||||||
Medical condition: Early Alzheimer Disease including mild cognitive impairment (MCI) due to AD/Prodromal AD and the early stages of mild AD | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (Prematurely Ended) ES (Prematurely Ended) CZ (Completed) AT (Prematurely Ended) BG (Prematurely Ended) GR (Completed) FR (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-000108-27 | Sponsor Protocol Number: H8A-MC-LZBE | Start Date*: 2016-08-25 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab versus Placebo in Prodromal Alzheimer’s Disease | |||||||||||||
Medical condition: Prodromal Alzheimer’s Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) PL (Prematurely Ended) DE (Prematurely Ended) NL (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000986-17 | Sponsor Protocol Number: ALZ-801-201ADBM | Start Date*: 2020-09-11 |
Sponsor Name:Alzheon Inc. | ||
Full Title: A Phase 2, Single Arm, Study of the Biomarker Effects of ALZ-801 in Subjects with Early Alzheimer’s Disease Who Are Carriers of the ε4 Variant of the Apolipoprotein E Gene (APOE4/4 or APOE3/4) | ||
Medical condition: Subjects with a clinical diagnosis of Alzheimer's disease who are APOE 4 carriers (APOE4/4, APOE3/4) and at the Early stage of disease, ages 50-80 years | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Trial now transitioned) NL (Trial now transitioned) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
